Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mylan Partner Mabion Withdraws Rituximab In EU

US Firm Had Been Hopeful Of Launch This Year

Executive Summary

Mabion’s European applications for biosimilar rituximab have been withdrawn, shortly after partner Mylan indicated it was hopeful of potential market entry this year, with a change of strategy necessitating a new application be filed with the EMA.

You may also be interested in...



Pfizer Has Eyes On EU Rituximab Market Following EC Approval

Pfizer has received European Commission approval for the firm’s Ruxience biosimilar to Roche’s MabThera brand, including as a treatment for rheumatoid arthritis, opening the door to a three-way biosimilar fight in the European Union.

Mylan’s ‘Durable’ Model Has Helped Weather Storms

Mylan says its ‘durable’ business model has helped it to withstand pressures from adverse industry trends in 2019, boosted by $1bn in sales from newly-launched products. However, negative currency effects cut the firm’s sales growth from 3% at constant currencies to 1% as reported.

Pfizer’s Ruxience Rituximab Biosimilar Gets CHMP Nod

Pfizer has received a positive opinion from the CHMP recommending granting a pan-European marketing authorization for its Ruxience rituximab biosimilar version of MabThera. At the same time, CHMP nods for hybrid medicines were received by SciPharm and Teva, while Mylan, Betapharm and Accord saw generics endorsed by the committee.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB149763

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel